Literature DB >> 21792894

Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.

Vanessa M Yu1, Christine M Marion, Theresa M Austria, Jennifer Yeh, Axel H Schönthal, Louis Dubeau.   

Abstract

Cancers that develop in BRCA1 mutation carriers are usually near tetraploid/polyploid. This led us to hypothesize that BRCA1 controls the mitotic checkpoint complex, as loss of such control could lead to mitotic errors resulting in tetraploidy/polyploidy and subsequent aneuploidy. We used an in vitro system mimicking premalignant conditions, consisting of cell strains derived from the benign counterparts of serous ovarian carcinomas (cystadenomas) and expressing SV40 large T antigen, conferring the equivalent of a p53 mutation. We previously showed that such cells undergo one or several doublings of their DNA content, as they age in culture and approach the phenomenon of in vitro crisis. Here, we show that such increase in DNA content reflects a cell cycle arrest possibly at the anaphase promoting complex, as evidenced by decreased BrdU incorporation and increased expression of the mitotic checkpoint complex. Down-regulation of BRCA1 in cells undergoing crisis leads to activation of the anaphase promoting complex and resumption of growth kinetics similar to those seen in cells before they reach crisis. Cells recovering from crisis after BRCA1 down-regulation become multinucleated, suggesting that reduced BRCA1 expression may lead to initiation of a new cell cycle without completion of cytokinesis. This is the first demonstration that BRCA1 controls a physiological arrest at the M phase apart from its established role in DNA damage response, a role that could represent an important mechanism for acquisition of aneuploidy during tumor development. This may be particularly relevant to cancers that have a near tetraploid/polyploid number of chromosomes.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792894      PMCID: PMC3299830          DOI: 10.1002/ijc.26309

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Authors:  Y Lee; A Miron; R Drapkin; M R Nucci; F Medeiros; A Saleemuddin; J Garber; C Birch; H Mou; R W Gordon; D W Cramer; F D McKeon; C P Crum
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

2.  Cell cycle control of BRCA2.

Authors:  J P Vaughn; F D Cirisano; G Huper; A Berchuck; P A Futreal; J R Marks; J D Iglehart
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

3.  BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner.

Authors:  Y Chen; A A Farmer; C F Chen; D C Jones; P L Chen; W H Lee
Journal:  Cancer Res       Date:  1996-07-15       Impact factor: 12.701

4.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product.

Authors:  L C Wu; Z W Wang; J T Tsan; M A Spillman; A Phung; X L Xu; M C Yang; L Y Hwang; A M Bowcock; R Baer
Journal:  Nat Genet       Date:  1996-12       Impact factor: 38.330

5.  Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.

Authors:  M P Luo; B Gomperts; S Imren; Y A DeClerck; M Ito; M Velicescu; J C Felix; L Dubeau
Journal:  Gynecol Oncol       Date:  1997-12       Impact factor: 5.482

6.  Association of BRCA1 with Rad51 in mitotic and meiotic cells.

Authors:  R Scully; J Chen; A Plug; Y Xiao; D Weaver; J Feunteun; T Ashley; D M Livingston
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

7.  The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.

Authors:  Barbara M Norquist; Rochelle L Garcia; Kimberly H Allison; Chris H Jokinen; Lauren E Kernochan; Catherine C Pizzi; Bethany J Barrow; Barbara A Goff; Elizabeth M Swisher
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

8.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.

Authors:  G E Tomlinson; T T Chen; V A Stastny; A K Virmani; M A Spillman; V Tonk; J L Blum; N R Schneider; I I Wistuba; J W Shay; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

9.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Authors:  Elizabeth M Swisher; Wataru Sakai; Beth Y Karlan; Kaitlyn Wurz; Nicole Urban; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase.

Authors:  S S Taylor; E Ha; F McKeon
Journal:  J Cell Biol       Date:  1998-07-13       Impact factor: 10.539

View more
  9 in total

1.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

2.  Enhanced susceptibility of ovaries from obese mice to 7,12-dimethylbenz[a]anthracene-induced DNA damage.

Authors:  Shanthi Ganesan; Jackson Nteeba; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2014-10-22       Impact factor: 4.219

3.  Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.

Authors:  Theresa Austria; Christine Marion; Vanessa Yu; Martin Widschwendter; David R Hinton; Louis Dubeau
Journal:  Int J Cancer       Date:  2018-10-03       Impact factor: 7.396

4.  Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.

Authors:  Louis Dubeau
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

Review 5.  Coming into focus: the nonovarian origins of ovarian cancer.

Authors:  L Dubeau; R Drapkin
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

6.  Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs.

Authors:  Hai-Yun Yen; Yankel Gabet; Ying Liu; Anthony Martin; Nancy L Wu; Malcolm C Pike; Baruch Frenkel; Robert Maxson; Louis Dubeau
Journal:  Lab Invest       Date:  2012-04-09       Impact factor: 5.662

7.  DNA methylation signatures to predict the cervicovaginal microbiome status.

Authors:  Nuno R Nené; James Barrett; Allison Jones; Iona Evans; Daniel Reisel; John F Timms; Tobias Paprotka; Andreas Leimbach; Dorella Franchi; Nicoletta Colombo; Line Bjørge; Michal Zikan; David Cibula; Martin Widschwendter
Journal:  Clin Epigenetics       Date:  2020-11-23       Impact factor: 6.551

8.  The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.

Authors:  Yan Wang; Ziliang Wang; Zihao Qi; Sheng Yin; Na Zhang; Yang Liu; Mingming Liu; Jiao Meng; Rongyu Zang; Zhen Zhang; Gong Yang
Journal:  Mol Cancer       Date:  2014-04-28       Impact factor: 27.401

9.  TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.

Authors:  Daniel Bronder; Anthony Tighe; Darawalee Wangsa; Dali Zong; Thomas J Meyer; René Wardenaar; Paul Minshall; Daniela Hirsch; Kerstin Heselmeyer-Haddad; Louisa Nelson; Diana Spierings; Joanne C McGrail; Maggie Cam; André Nussenzweig; Floris Foijer; Thomas Ried; Stephen S Taylor
Journal:  Dis Model Mech       Date:  2021-11-30       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.